Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
British Journal of Haematology
|
September 12, 1998
Inhibited apoptosis and drug resistance in acute myeloid leukaemia
B D Smith, B J Bambach, M S Vala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
E K Rowinsky, A Adjei, R C Donehower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia
E K Rowinsky, S H Kaufmann, S D Baker, et al.
Leukemia Research
|
March 28, 2002
Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy
E M Sotomayor, S Piantadosi, C B Miller, et al.
Leukemia
|
October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G Garcia-Manero, S D Gore, S Kambhampati, et al.
Annals of the New York Academy of Sciences
|
December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samples
S H Kaufmann, S D Gore, L Letendre, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia
S D Gore, E K Rowinsky, C B Miller, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
British Journal of Haematology
|
September 12, 1998
Inhibited apoptosis and drug resistance in acute myeloid leukaemia
B D Smith, B J Bambach, M S Vala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
E K Rowinsky, A Adjei, R C Donehower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia
E K Rowinsky, S H Kaufmann, S D Baker, et al.
Leukemia Research
|
March 28, 2002
Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy
E M Sotomayor, S Piantadosi, C B Miller, et al.
Leukemia
|
October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G Garcia-Manero, S D Gore, S Kambhampati, et al.
Annals of the New York Academy of Sciences
|
December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samples
S H Kaufmann, S D Gore, L Letendre, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia
S D Gore, E K Rowinsky, C B Miller, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Page
of 5